Last reviewed · How we verify
Intravenous iron sucrose
Iron sucrose is a carbohydrate complex that delivers iron directly into the bloodstream to replenish iron stores and support hemoglobin synthesis in patients with iron deficiency.
Iron sucrose is a carbohydrate complex that delivers iron directly into the bloodstream to replenish iron stores and support hemoglobin synthesis in patients with iron deficiency. Used for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in patients with chronic kidney disease not on dialysis, Iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease.
At a glance
| Generic name | Intravenous iron sucrose |
|---|---|
| Also known as | Intravenous iron sucrose(Sacrofer 100mg/5ml) was manufactured by Amoun company for pharmaceutical and chemical industry ,Egypt., Noripurum, Venofer Luitpold Pharmaceuticals, NDC # 00517-2340-10, Fermed® 100mg |
| Sponsor | Ain Shams University |
| Drug class | Iron replacement agent |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Iron sucrose is a stable complex of iron (III) hydroxide with sucrose that allows safe intravenous administration of iron. The complex is taken up by cells of the reticuloendothelial system, where iron is released and incorporated into hemoglobin and other iron-dependent proteins. This bypasses gastrointestinal absorption limitations and is particularly useful in patients with chronic kidney disease on hemodialysis who cannot tolerate or absorb oral iron adequately.
Approved indications
- Iron deficiency anemia in patients with chronic kidney disease on hemodialysis
- Iron deficiency anemia in patients with chronic kidney disease not on dialysis
- Iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease
Common side effects
- Hypotension
- Headache
- Nausea
- Vomiting
- Abdominal pain
- Injection site reactions
- Anaphylactic reactions
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients (NA)
- Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients (NA)
- Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin (PHASE2)
- Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy (PHASE3)
- Perioperative Blood Conservation: Role of Combined Iron Supplementation Protocols in Reducing Allogeneic Transfusion (NA)
- Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis (PHASE3)
- The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous iron sucrose CI brief — competitive landscape report
- Intravenous iron sucrose updates RSS · CI watch RSS
- Ain Shams University portfolio CI